Main topics 2018


selected indicators 2018

entire Switzerland


Peter Hug



Medicine is advancing at a rapid pace at present. The trend in the research and treatment of cancer, for example, is moving towards individually tailored treatments depending on the stage of the disease and the genetic subtype of the patient. New medicines are also being increasingly used in combination, although the benefits of a medication can differ from one indication to another. In the next five years, we expect to see several hundred approvals of new products, new indications and combinations of innovative medicines.


The growing number of more effective therapies is good news for patients. They will have more treatment options at their disposal in future. But this development also poses a challenge for authorities, hospitals, physicians, health insurers and the pharmaceutical industry, as well as our pricing system. We have made progress in the field of reimbursement for combination therapies, indication-specific prices and other models, which have already come into use in various cases. But to develop our good-quality healthcare system further and find shared solutions, we need to step up the dialogue. A start has been made with the stakeholder platform SanteneXt, which was co-founded by Interpharma. The platform brings together various actors to address present challenges with concrete approaches based on pilot projects and thus ultimately contribute to the further development of our healthcare system.


René Buholzer



The pharmaceutical industry has been the most important driver of growth in various regions of Switzerland over the past few years and hence an engine for the economy as a whole. The pharmaceutical industry accounts for around one-fifth of Switzerland’s real GDP growth. Innovation-friendly framework conditions are needed to ensure that this ball keeps rolling and that the interplay between large export-oriented companies and small to medium-sized enterprises can also contribute to the prosperity of Switzerland in the future.


In addition to strong patent protection, these framework conditions include an attractive tax environment that is internationally accepted and also openness to business. Around 50 percent of pharmaceutical exports go to EU countries. For this reason, the bilateral agreements, which guarantee unbureaucratic access to this important trading partner of Switzerland, are of particular importance if the export business is to continue flourishing. Interpharma member companies invest around 7 billion francs in research and development each year in Switzerland. To ensure that such investments continue, it is essential that innovation is rewarded in terms of prices in the future and that patients have quick access to innovative therapies.